Success Stories: NIW Approval Secured for Biomedical Materials Research Scientist
Client’s Testimonial:
“Thank you for the great news and help throughout the process.”
On August 20th, 2025, we received another EB-2 NIW (National Interest Waiver) approval for a Research Scientist in the Field of Biomedical Materials (Approval Notice).
General Field: Biomedical Materials
Position at the Time of Case Filing: Research Scientist
Country of Origin: China
State of Residence at the Time of Filing: Washington
Approval Notice Date: August 20th, 2025
Processing Time: 6 months (Premium Processing Requested)
Case Summary:
North America Immigration Law Group (NAILG) is pleased to announce the EB-2 NIW (National Interest Waiver) approval of a research scientist from China specializing in biomedical materials. The petition was filed on February 20, 2025, and approved on August 20, 2025, with the help of premium processing.
Breakthrough Research in Drug Delivery
The client’s work focuses on biomolecular delivery vehicles to create novel drug delivery systems that enhance targeted treatment efficiency and improve therapeutic outcomes. His research addresses urgent healthcare needs, such as cancer therapy and chronic disease management, by designing materials that enhance drug targeting, controlled release, and overall bioavailability.
Accomplishments and Recognition
- Publications: 4 peer-reviewed journal articles in top-ranked journals, including Nano Letters and Journal of Materials Chemistry B.
- Citations: His studies have already accumulated 148 citations, with two papers ranked among the top 10% and 20% most cited works of their publication years.
- Funding: His research has received support from major health institutes, further validating the national importance of his work.
These contributions have advanced not only the science of biomaterials but also precision medicine and therapeutic innovation, ensuring his work directly benefits U.S. public health priorities.
Why USCIS Approved the Petition
In preparing the petition, NAILG demonstrated that:
- His research has substantial merit in addressing cancer and chronic disease therapies.
- His contributions are of national importance, directly tied to healthcare innovation and U.S. scientific competitiveness.
- He is well-positioned to continue advancing his work given his track record of publications, citations, peer recognition, and ongoing projects.
On balance, USCIS agreed that waiving the labor certification requirement was beneficial to the United States, leading to his EB-2 NIW approval.
NIW Approval and Outlook
With his NIW approval secured, the client is now well-placed to expand his pioneering research in the U.S., contributing to the development of next-generation drug delivery systems and strengthening America’s role in biomedical innovation.
At NAILG, we are proud to have guided this case to success and look forward to seeing his continued contributions improve health outcomes and shape the future of therapeutic science.

